LCM
HOWL icon

Lynx1 Capital Management’s Werewolf Therapeutics HOWL Stock Holding History

Lynx1 Capital Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Buy
657,786
+1,860
+0.3% +$1.27K 0.09% 18
2025
Q4 		$416K Buy
+655,926
New +$797K 0.08% 18

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Lynx1 Capital Management's HOWL Position: Q1 2026 in Review

Lynx1 Capital Management increased its Werewolf Therapeutics (HOWL) stake by 0.28% in Q1 2026, buying an estimated $1.27K and bringing the position to 657,786 shares worth $548K. The position accounts for 0.09% of the portfolio, ranked #18.

Lynx1 Capital Management first reported a position in HOWL in Q4 2025 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Lynx1 Capital Management held 657,786 shares of Werewolf Therapeutics worth $548K as of Q1 2026.
  • Lynx1 Capital Management bought 1,860 Werewolf Therapeutics shares in Q1 2026, an estimated $1.27K.
  • Werewolf Therapeutics made up 0.09% of Lynx1 Capital Management's portfolio in Q1 2026, its #18 holding.
  • Lynx1 Capital Management first reported a position in Werewolf Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Lynx1 Capital Management's 13F filing for Q1 2026, filed 4 May 2026.